P. Narayan et H. Lepor, Long-term, open-label, phase III multicenter study of tamsulosin in benignprostatic hyperplasia, UROLOGY, 57(3), 2001, pp. 466-470
Objectives. To investigate the long-term efficacy and safety of tamsulosin
in patients with benign prostatic hyperplasia and to monitor the increases
and decreases in therapeutic response over time. Tamsulosin, a uroselective
alpha-adrenergic receptor antagonist for the treatment of lower urinary tr
act symptoms due to benign prostatic hyperplasia, targets alpha(1A)-adrener
gic receptors of prostatic smooth muscle with greater affinity than the vas
cular alpha,, receptors. Since the alpha(1A)-adrenoceptor subtype mediates
prostatic smooth muscle tension, alpha(1A)-adrenoceptor antagonists may dim
inish toxicity, with few unwanted effects on blood pressure, while still pr
oviding efficacious treatment.
Methods. This study extended two 13-week trials and one 40-week extension t
rial for an additional 64 weeks. On study entry, all patients (n = 949) rec
eived 0.4 mg/day tamsulosin. Baseline values were taken from either those o
f the previous trials for patients who had been treated with tamsulosin or
the first visit of this study for patients not previously exposed to the dr
ug. The primary efficacy parameters were the changes in the total American
Urological Association (AUA) symptom score, mean peak urinary flow rate (Qm
ax), and percentage of patients having 25% or greater improvement in the to
tal AUA symptom score and 30% or more improvement in the Qmax. Safety was a
ssessed primarily on the incidence and severity of adverse events and disco
ntinuations due to adverse events.
Results. Improvements from baseline were seen in all primary efficacy param
eters and were maintained throughout the study. The changes from baseline f
or the total AUA symptom score and Qmax were statistically significant (P <
0.001) at all 3-month intervals. Tamsulosin was well tolerated, and the in
cidence of adverse events did not increase over time. The mean sitting vita
l signs did not vary from baseline or relative to the treatment duration.
Conclusions. Tamsulosin was safe and effective in long-term treatment (long
er than 1 year) of benign prostatic hyperpasia. UROLOGY 57: 466-470, 2001,
(C) 2001, Elsevier Science Inc.